Risk of Severe COVID May Hinge on Type of Asthma
Some studies have suggested that people who have asthma caused by something other than allergies -- exercise, stress, air pollution, weather conditions -- might have an increased risk of severe COVID-19.
Vaccine-related severe allergic reactions are of growing public concern given reports of anaphylaxis after COVID-19 mRNA vaccination1 and may contribute to vaccine hesitancy and incomplete vaccination.2 Little is known about prior trends in healthcare utilization for vaccine-related severe allergic reactions among the United States (US) adult population.3 Understanding these trends over time, especially prior to the COVID-19 pandemic, may be helpful to contextualize COVID-19 vaccine-related allergic reactions and inform public understanding of the overall risk of vaccine-related severe allergic reactions.
Ann Allergy Asthma Immunol. 2021 Dec;127(6):703. doi: 10.1016/j.anai.2021.09.007.NO ABSTRACTPMID:34823756 | PMC:PMC8608549 | DOI:10.1016/j.anai.2021.09.007
Conclusions: Only a minority of this population tested positive for COVID-19 and none of them developed serious disease, supporting the evidence that both severe type-2 asthma and its targeted treatment do not convey increased risk for disease. However, additional studies regarding long-term complications should also be performed.
Conclusion: Our study shows that the prevalence of asthma among covid-19 patients is similar to the prevalence in the general population, asthmatic patients are not more prone than others to catching the virus and asthma is not a risk factor for severe outcomes.
ConclusionCollectively, our findings indicated that the MQ-VET is a valid and reliable tool that will help to standardize future evaluations of online medical videos.
Background: COVID19 did not demonstrate more frequent or severe disease in asthmatic children, but few is known on its effect on symptoms and lung function.Objectives: To compare asthma symptoms and lung function during first and two last quarters of 2019 with these of 2020.Methods: Retrospective study in asthmatic children seen for lung function assessment. Proportions of children and functional indexes were compared using Chi-2 and t-Student tests, respectively.Results: Distribution of 3419 files across the first, and two last quarters of 2019 and 2020 was 672, 542, 657, and 476, 495 and 577, respectively. Asthma control...
Survivors of Coronavirus disease 2019 frequently experience an array of symptoms following discharge from hospital. The most common symptoms after severe COVID-19 disease and hospitalization are fatigue, breathlessness and joint pain. (C. A. et al. JAMA. 2020; 324(6):603-605. and S. W. et al. BMJ. 2021; 372:n136) However, medium and long-term symptoms experienced by patients with mild or moderate COVID-19 remain unclear. We retrospectively analyzed a descriptive case series of 46 patients monitored in an outpatient pneumologist’s clinic at three timepoints (one, three and six months) after COVID-19 infection. No pati...
Introduction: The paediatric respiratory and allergy teams in Cambridge Hospital see patients with atopic and overlapping conditions, thus increasing travel for patients and hospital footfall. It is a tertiary reference hospital covering East England. Assessment of practice and changes of the service, in view of COVID-19 pandemic.Method: Retrospective assessment of patients: a) referred between the specialties (1/4/19- 31/3/20), investigations booked (lung function, skin prick testing, specific IgE, peak flow, inhaler and nasal spray technique) and patient flow. b) currently being seen by both teams (1/4/18-31/3/20).R...
Conclusion: COVID-19 measures have a positive and negative influence on the course of disease in asthmatics. The observed improvement can be contributed to a significant reduction in exposure to viral infections. Long-term observation of this side-effect may help improve our understanding of the influence of viral infections on asthma in early childhood.
CONCLUSION: These technological advances provide distinct advantages to the provider and patient, but also have a burden of time for evaluation of the data for the provider and disparate access to certain technologies for patients. The development of these technologies has been fast-tracked since the start of the Covid-19 pandemic. With the explosion in telehealth and medical device development, advancement of medical technology is not showing any signs of slowing down. It is paving a new way to interact with patients in the future.PMID:34813954 | DOI:10.1016/j.anai.2021.11.013